

## **22 September 2021**

### **eTheRNA immunotherapies conference attendance from September to October 2021**

**Niel (Belgium)** eTheRNA immunotherapies NV ('eTheRNA'), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences from September through to October 2021:

#### **[FlandersBio - Knowledge for Growth](#)**

27–29 September 2021

Michael Mulqueen, VP of Business Development, will be speaking as part of the 'The Power of Cell & Gene-Personalised Medicine' panel on Tuesday, 28 September from 11:00am-12:00pm CET.

Tim Van Assche, Director of Business Development and Alliance Management, and Johanna Madero, Communications Coordinator, will be in attendance.

#### **[Optimum Healthcare Investor Conference](#)**

4 October 2021

Mathieu Lane, Chief Financial Officer, and President of eTheRNA Inc., will be in attendance.

#### **[AACR Virtual Conference on Tumour Immunology and Immunotherapy](#)**

5-6 October, 2021

Anna Kuchmiy, Discovery Scientist, will be in attendance.

#### **[Access Biotech China](#)**

14-15 October 2021

Steven Powell, Chief Executive Officer, will be speaking as part of the 'Partnering with Chinese Companies and/or Investors' panel, on Thursday, 14 October from 9:00am-10:30am CET.

#### **[Bio-Europe](#)**

25-28 October 2021

Michael Mulqueen, VP of Business Development, and Tim Van Assche, Director of Business Development and Alliance Management, will be in attendance.

#### **[Biologics Contract Manufacturing Europe](#)**

27-28 October 2021

Bernard Sagaert, COO and SVP of Manufacturing, will be speaking as part of the 'GMP Manufacturing Requirements and Processes' panel on Thursday, 28 October 2021 from 9:00am-9:30am CET.

David Ricketts, Director of Business Development, will be in attendance.

**For more information, please contact:**

**eTheRNA immunotherapies**

Johanna Madero

media@etherna.be

**Notes to Editors**

**About eTheRNA immunotherapies**

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA chemistry, antigen identification, lipid chemistry and delivery and process engineering platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA's R&D pipeline can be found at <https://www.etherna.be/immunotherapies-rd-pipeline/>.